Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.

Subcutaneous Keytruda plus chemotherapy met pharmacokinetic endpoints, showing noninferiority to the intravenous formulation in metastatic NSCLC treatment. The subcutaneous formulation, administered ...

Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab). This version, which will be marketed as ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in ...

Merck MRK announced that the European Commission has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Keytruda Qlex is now FDA-approved for subcutaneous use in patients 12 and older with solid tumors, offering an alternative to IV administration. Subcutaneous administration can improve patient ...

Keytruda, a Merck cancer immunotherapy that has become the world’s top-selling medication, is administered as an intravenous infusion over the course of 30 minutes. The pharmaceutical giant now has ...

Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...